Kendy “courtesy” letter
This article was originally published in The Tan Sheet
Executive Summary
FDA does not believe that the meaning of the "help maintain normal blood cholesterol levels" structure/function claim "limits the meaning of the claim to only effects on already normal cholesterol levels," the agency tells Kendy USA (Palatine, Ill.) in a recent exchange regarding a structure/function claim submission. Rather, it "includes effects on preventing elevations of cholesterol levels outside of the normal range and reduction of elevated cholesterol into the normal range." Kendy had maintained that since there was no reference to coronary heart disease and that the claim was not specific to reducing high cholesterol levels, the claim was appropriate...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.